CAMBRIDGE, MA—Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Sacco sold 3,890 shares of common stock on January 16, 2025, at a price of $44.1972 per share, totaling approximately $171,927. The transaction occurs as Scholar Rock’s stock trades near its 52-week high of $46.19, having delivered an impressive 395% return over the past six months. According to InvestingPro, the company maintains a FAIR financial health rating.
This transaction was not discretionary but was mandated by the company’s equity incentive plans to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). InvestingPro subscribers have access to 13 additional key insights about Scholar Rock’s financial position and market performance. Following the sale, Sacco retains ownership of 45,395 shares, consisting of 8,431 shares of common stock and 36,964 RSUs, while the company maintains strong liquidity with a current ratio of 3.88, indicating healthy short-term financial stability.
In other recent news, Scholar Rock, a biopharmaceutical company, is moving towards the commercialization of apitegromab, a potential treatment for spinal muscular atrophy (SMA). The company plans to submit regulatory applications in the first quarter of 2025, with a U.S. launch anticipated in the fourth quarter of the same year. Analysts from firms such as H.C. Wainwright, Truist Securities, and BMO Capital Markets have raised their price targets for Scholar Rock, reflecting their positive outlook on the company’s growth potential.
The company is also advancing its cardiometabolic program, with topline data from the Phase 2 EMBRAZE trial in obesity expected in the second quarter of 2025. In addition, Scholar Rock is developing SRK-439, another candidate targeting obesity, with an Investigational New Drug (IND) application filing expected in the third quarter of 2025.
Scholar Rock has initiated the Phase 2 OPAL clinical trial for SMA patients under two years old, following the positive results from the pivotal Phase 3 SAPPHIRE trial. These developments, along with a robust financial position and a healthy current ratio, underline Scholar Rock’s commitment to addressing unmet needs in the medical field and expanding the potential benefits of apitegromab.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.